EU Considers Curbing Antibiotic Use

The European Medicines Agency has recommended that farmers stop using the antibiotic colistin prophylactically, citing human health concerns.

Written byChris Palmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA COMMONS, DOHDUHDAHReflecting growing worries about the overuse of antibiotics contributing to the global public health threat of drug-resistant bacterial infections in humans, the European Medicines Agency (EMA) has suggested a ban on the blanket use of the antibiotic colistin for farm animals, Nature reported Tuesday (July 30). The agency said that colistin, which has been used by veterinarians for more than 50 years, should still be made available, but that the drug’s use should be restricted to infected animals or animals in contact with infections. The European Commission will soon make a decision about the proposed restriction.

The EMA also indicated that there was no evidence in support of the prophylactic use of another antibiotic called tigecycline, which is not currently approved for use in animals, though the agency fell short of a formal recommendation for guidelines on its use. Both colistin and tigecycline are regularly prescribed in human medicine as life-saving treatments against infections caused by multidrug-resistant bacteria.

“The EMA recommendation is the precautionary approach, and is laudable,” Laura Piddock, a microbiologist at the University of Birmingham in the U.K. and director of Antibiotic Action, which encourages the development of new antibiotics, told Nature. “The reality is that we should question the use of any antibacterial agent outside of human medicine and until there is unequivocal evidence showing no effect of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies